Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Science Stream

DCS9 - Emerging Adjuvant Therapies in Type 1 Diabetes (& LADA)

Thursday, November 27, 2025
14:30 - 15:45 Toronto
Location: Room 206

    Speaker(s)

  • Melissa-Rosina Pasqua, MD, FRCPC, PhD (she/her/hers)

    Clinician-scientist
    McGill University Health Centr
    McGill University
    Montreal, Quebec, Canada

    Disclosure(s): Abbott: Speaker/Honoraria (Terminated, September 1, 2024); Medtronic: Speaker/Honoraria (Terminated, September 15, 2023); Sanofi: Speaker/Honoraria (Terminated, December 15, 2024)

  • Alanna Weisman, MD, PhD, FRCPC (she/her/hers)

    Assistant Professor
    University of Toronto
    University of Toronto
    Toronto, Ontario, Canada

    Disclosure(s): Breakthrough T1D: Grant/Research Support (Ongoing); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Terminated, September 1, 2025); CPD Network: Speaker/Honoraria (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); Diabetes Care Community: Speaker/Honoraria (Ongoing); Noble Insights: Speaker/Honoraria (Terminated, September 1, 2025); Ontario Health: Grant/Research Support (Ongoing)

  • Nadine Taleb, MD, PhD

    Assistant professor
    Université de Montréal
    Université de Montréal
    laval , Quebec, Canada

    Disclosure(s): Dexcom: Speaker/Honoraria (Terminated, July 1, 2024); Novo Nordisk: Speaker/Honoraria (Terminated, July 20, 2025); Sanofi: Speaker/Honoraria (Terminated, July 20, 2025)

    • Moderator(s)

  • LORRAINE LIPSCOMBE, MD, MSc, FRCPC (she/her/hers)

    Professor
    University of Toronto and Women's College Hospital
    University of Toronto
    Toronto, Ontario, Canada

    Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Disclosure(s):
Melissa-Rosina Pasqua, MD, FRCPC, PhD: Abbott: Speaker/Honoraria (Terminated, September 1, 2024); Medtronic: Speaker/Honoraria (Terminated, September 15, 2023); Sanofi: Speaker/Honoraria (Terminated, December 15, 2024)
Alanna Weisman, MD, PhD, FRCPC: Breakthrough T1D: Grant/Research Support (Ongoing); Canadian Institutes of Health Research (CIHR): Grant/Research Support (Terminated, September 1, 2025); CPD Network: Speaker/Honoraria (Ongoing); Diabetes Canada: Grant/Research Support (Ongoing); Diabetes Care Community: Speaker/Honoraria (Ongoing); Noble Insights: Speaker/Honoraria (Terminated, September 1, 2025); Ontario Health: Grant/Research Support (Ongoing)
Nadine Taleb, MD, PhD: Dexcom: Speaker/Honoraria (Terminated, July 1, 2024); Novo Nordisk: Speaker/Honoraria (Terminated, July 20, 2025); Sanofi: Speaker/Honoraria (Terminated, July 20, 2025)
LORRAINE LIPSCOMBE, MD, MSc, FRCPC: I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Learning Objectives: This session will:
• Describe how adjuvant therapies – including GLP-1 receptor antagonists, SGLT2 inhibitors, and metformin – may be used in combination with insulin to help manage blood glucose and improve clinical outcomes in T1D
• Apply knowledge of drug mechanism of action to understand how different type 2 diabetes medications may have utility in T1D
• Describe how adjuvant therapies are being used in other types of diabetes, including LADA